Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukemia: A model for drug development

M J Keating1

  • 1University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.

Leukemia·2017
Same author

ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).

Blood cancer journal·2016
Same author

New Agents and Strategies in CLL Treatment.

Leukemia & lymphoma·2016
Same author

Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia.

Leukemia & lymphoma·2016
Same author

Adhesion of B-Cell Chronic Lymphocytic Leukemia Cells to Marrow Stromal Cells is Mediated by α4β1 but not β2αL Integrin: MSC also Prevent Apoptosis of B-CLL Cells.

Hematology (Amsterdam, Netherlands)·2016
Same author

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

Leukemia·2016
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Leukemia research has driven advances in cancer drug development, leading to new combination therapies and understanding drug activity. Novel agents like 506U78 show promise for future treatments.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Leukemia and lymphoma models were foundational in early cancer drug development.
  • Leukemia research pioneered concepts like combination chemotherapy and remission induction.

Purpose of the Study:

  • To highlight the historical impact of leukemia research on cancer drug development.
  • To discuss the evolution of understanding drug mechanisms and therapeutic potential, exemplified by fludarabine monophosphate (Fludara).

Main Methods:

  • Review of historical preclinical and clinical studies in leukemia.
  • Analysis of drug mechanisms, including fludarabine monophosphate's biochemical actions.
  • Examination of novel agent development, such as compound 506U78.

Related Experiment Videos

Main Results:

  • Leukemia models established key chemotherapy principles and demonstrated the impact of cytogenetics on treatment response.
  • Fludarabine monophosphate (Fludara) showed efficacy in advanced leukemia, leading to FDA approval and expanded use in combination therapies.
  • Compound 506U78, an arabinosyl guanosine analog, exhibits potent activity in acute T-cell leukemia and shares Fludara's mechanisms.

Conclusions:

  • Leukemia's accessibility for study has been crucial for advancing cancer drug development and understanding novel agent activities.
  • Fludara's evolving therapeutic applications demonstrate the potential for biochemical modulation in cancer treatment.
  • Compound 506U78 represents a promising new agent with potential for broad application in hematologic malignancies.